.jpg "Dmitry Manuilov, MD photo")
Sr. Director, Virology Clinical Development
Gilead Sciences, Inc.
Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)
Dmitry Manuilov, MD | Gilead Sciences, Inc.
Biography
After graduating from the State Medical University in Moscow, Dmitry started his career in Clinical Research in pharmaceutical industry where he contributed to the development of a novel therapy for breast cancer and branded generics as well as took leadership roles in some of the corporate initiatives. Dmitry then moved on to biotech / venture capital environment where he helped manage the clinical development program of an innovative gastrointestinal product and successfully contributed to other programs and projects.
In 2017 Dmitry joined MYR GmbH to lead the clinical development of bulevirtide – a novel breakthrough entry inhibitor for the treatment of chronic HDV infection. During this time, the team completed phase 2b studies, launched an international phase 3 program, and ensured granting the Conditional Marketing Authorization of bulevirtide in the EU. Following the acquisition of MYR GmbH by Gilead Sciences in 2021, he moved to Gilead to continue contributing to the development of bulevirtide and help addressing the unmet medical need worldwide.
Dmitry’s area of scientific interest is focused on viral hepatitis, especially HBV/HDV co-infection. He is also interested in various aspects of drug development and clinical research, such as streamlining drug development, implementation of innovative study designs, ethical considerations, and harmonization of international regulations.
Related programs
International Workshop on HBV Cure 2021
• Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV
International Workshop on HBV Cure 2023
• Value of Bulevirtide Combination with PEG-IFN in HDV